Publicacions en què col·labora amb Paula Aranaz Oroz (21)

2021

  1. In vivo testing of mucus-permeating nanoparticles for oral insulin delivery using Caenorhabditis elegans as a model under hyperglycemic conditions

    Acta Pharmaceutica Sinica B, Vol. 11, Núm. 4, pp. 989-1002

2020

  1. A combination of borage seed oil and quercetin reduces fat accumulation and improves insulin sensitivity in obese rats

    Food and Function, Vol. 11, Núm. 5, pp. 4512-4524

  2. Phenolic compounds reduce the fat content in caenorhabditis elegans by affecting lipogenesis, lipolysis, and different stress responses

    Pharmaceuticals, Vol. 13, Núm. 11, pp. 1-33

2019

  1. Broccoli extract improves high fat diet-induced obesity, hepatic steatosis and glucose intolerance in Wistar rats

    Journal of Functional Foods, Vol. 59, pp. 319-328

  2. Low doses of cocoa extract supplementation ameliorate diet-induced obesity and insulin resistance in rats

    Food and Function, Vol. 10, Núm. 8, pp. 4811-4822

  3. Phenolic compounds inhibit 3T3-L1 adipogenesis depending on the stage of differentiation and their binding affinity to PPARγ

    Molecules, Vol. 24, Núm. 6

2018

  1. Borago officinalis seed oil (BSO), a natural source of omega-6 fatty acids, attenuates fat accumulation by activating peroxisomal beta-oxidation both in C. elegans and in diet-induced obese rats

    Food and Function, Vol. 9, Núm. 8, pp. 4340-4351

  2. Cyclodextrin-grafted poly(anhydride) nanoparticles for oral glibenclamide administration. In vivo evaluation using C. elegans

    International Journal of Pharmaceutics, Vol. 547, Núm. 1-2, pp. 97-105

  3. Dihomo-gamma-linolenic acid induces fat loss in: C. Elegans in an omega-3-independent manner by promoting peroxisomal fatty acid β-oxidation

    Food and Function, Vol. 9, Núm. 3, pp. 1621-1637

2017

  1. p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation

    Haematologica

2014

  1. A simple approach for classifying new mutations as somatic or germinal in DNA samples lacking paired tissue

    BioTechniques, Vol. 56, Núm. 6, pp. 327-329

  2. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling

    Leukemia

2013

  1. CBL RING finger deletions are common in core-binding factor acute myeloid leukemias

    Leukemia and Lymphoma

  2. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 235-239

2012

  1. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia

    Leukemia and Lymphoma

  2. CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2

    Haematologica, Vol. 97, Núm. 8, pp. 1234-1241

2011

  1. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation

    Leukemia Research, Vol. 35, Núm. 11, pp. 1537-1539

  2. Mecanismos genéticos de activación de vías de señalización celular en neoplasias mieloproliferativas crónicas BCR-ABL1 negativas

    Mecanismos genéticos de activación de vías de señalización celular en neoplasias mieloproliferativas crónicas BCR-ABL1 negativas

2010

  1. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes

    Cancer Genetics and Cytogenetics, Vol. 199, Núm. 1, pp. 1-8

  2. Quantification of PDGFRA alternative transcripts improves the screening for XPDGFRA fusions by reverse transcriptase-polymerase chain reaction

    Leukemia and Lymphoma, Vol. 51, Núm. 9, pp. 1720-1726